Table 3.

Comparing DSE-CSN-based model to the DSE-SBN-based model in the de novo cross-validation across different drug classes

Drug Class	SBN-based (MAP)	CSN-based (MAP)
Antineoplastic and immunomodulating agents	0.090	0.17
Alimentary tract and metabolism	0.15	0.27
Genito urinary system and sex hormones	0.29	0.46
Cardiovascular system	0.19	0.30
Nervous system	0.19	0.30
Musculo-skeletal system	0.30	0.45
Respiratory system	0.28	0.33
Dermatologicals	0.31	0.33